| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $361K | — | -78.0% |
| SG&A Expense | $1.6M | — | +16.4% |
| Operating Income | -$2.0M | — | +34.3% |
| Net Income | -$2.0M | — | +34.4% |
| EPS (Basic) | -$1.61 | — | +72.2% |
| EPS (Diluted) | -$1.61 | — | +72.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.0M | +34.3% | +236.7% |
| Current Assets | $11.3M | +31.3% | +187.0% |
| Total Assets | $11.3M | +30.8% | +180.5% |
| Current Liabilities | $794K | -70.0% | -71.4% |
| Total Liabilities | $794K | -70.1% | -72.0% |
| Stockholders' Equity | $10.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.7M | — | -112.3% |
| Financing Cash Flow | $6.5M | — | — |
| +775.1% |